Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 6Peritoneal Neoplasms 2Colorectal Neoplasms 2Appendiceal Neoplasms 2Anus Neoplasms 2Uterine Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Solid Neoplasm 1Sarcoma 1Rectal Neoplasms 1Pleural Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mediastinal Neoplasms 1HIV Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 267Oxaliplatin 266Capecitabine 225Leucovorin 209Irinotecan 151Radiotherapy 132Bevacizumab 112Cetuximab 81Folfox protocol 49Surgical Procedures, Operative 44Radiation 41Drug Therapy 41Neoadjuvant Therapy 40Chemoradiotherapy 33Chemotherapy, Adjuvant 32Panitumumab 27XELOX 25Magnetic Resonance Spectroscopy 22Radiotherapy, Intensity-Modulated 21Floxuridine 17Biopsy 16Nivolumab 15Gemcitabine 15Early Intervention, Educational 15pembrolizumab 14Laparoscopy 14IFL protocol 14Celecoxib 14trifluridine tipiracil drug combination 13Gene Expression Profiling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rectal Neoplasms × Mitozytrex × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡